Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
· Financial Post
PARSIPPANY, N.J. -- Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study, with effects observed from as early as Day 7 after the first injection1. Lenivia targets nerve growth factor (NGF), a recognized mediator of pain and inflammation, and binds to a different site on NGF versus already commercialised anti-NGF mAbs. Read More
Visit turconews.click for more information.